Thomas Hutson, DO, PharmD, PhD, FACP

home / authors / thomas-hutson-do-pharmd-phd-facp

Articles

Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

Hans Hammers, MD, PhD;Thomas Hutson, DO, PharmD, PhD, FACP;Hannah Dzimitrowicz McManus, MD
March 10th 2025

Experts discuss the impact of tumor burden on postprogression survival, exploring strategies to optimize responses in renal cell carcinoma.

CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

Hans Hammers, MD, PhD;Thomas Hutson, DO, PharmD, PhD, FACP;Hannah Dzimitrowicz McManus, MD
March 10th 2025

Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
Published: May 17th 2013 | Updated: March 10th 2025
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer